{"filings":[{"id":2105992,"accession_number":"0001628280-26-054294","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2026-08-06T20:08:36+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q2 2026 revenue $125.8M (+11% YoY); net loss $(13.5M) vs prior year net income","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $125.8M, up 11% GAAP (9% constant currency) YoY; net loss $(13.5M) or $(0.28)/share vs net income $1.3M in Q2 2025.","Non-GAAP net income $6.3M ($0.13/share) vs $10.7M ($0.24/share) in Q2 2025; adjusted EBITDA $26.4M, up 7% YoY.","On-X revenue grew 18% constant currency; stent grafts grew 12% constant currency; AMDS and NEXUS highlighted.","Received U.S. FDA PMA approval for AMDS Hybrid Prosthesis; completed acquisition of Endospan Ltd. in May 2026.","Reiterated FY2026 revenue guidance $480-496M (7-11% constant currency growth) and adjusted EBITDA $92-99M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":481997,"accession_number":"0001628280-26-035798","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2026-05-18T11:06:12+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Artivion completes $135M acquisition of Endospan; adds Nexus aortic stent graft","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Net purchase price of $135M funded via $150M delayed draw term loan.","Contingent consideration up to $200M based on Nexus product performance, payable ~2 years post-close.","FDA approved Premarket Approval for Nexus branched endovascular stent graft system in April 2026.","Acquisition completes Artivion's aortic arch portfolio alongside AMDS and ARCEVO LSA devices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":468356,"accession_number":"0001628280-26-035507","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2026-05-15T19:13:32+00:00","items":["5.07","9.01"],"status":"ready","headline":"Artivion stockholders elect all nine director nominees and approve say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine nominees elected; highest vote count for Anthony B. Semedo (39,241,704 for) and lowest for Jeffrey H. Burbank (34,250,202 for).","Say-on-pay passed with 36,876,134 votes for, 2,291,059 against, and 151,868 abstentions.","Ernst & Young LLP ratified as independent auditor for FY 2026 with 44,294,062 for, 625,438 against.","Broker non-votes of 5,607,747 on director elections and say-on-pay were reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":98826,"accession_number":"0001628280-26-032097","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["1.01","2.02","9.01"],"status":"ready","headline":"Artivion Q1 rev $116M, net income $1.4M; lowers FY outlook; exercises Endospan option for ~$135M net","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Q1 revenue $116.3M (+18% GAAP, +12% constant currency YoY); net income $1.4M ($0.03 diluted EPS) vs net loss $0.5M in Q1 2025.","Adjusted EBITDA $22.1M (+26% YoY); non-GAAP net income $4.2M ($0.08 diluted EPS) vs $2.5M ($0.06) in prior year.","Full-year 2026 revenue guidance lowered to $480-496M (prev $486-504M); adjusted EBITDA guidance lowered to $100-107M (prev $105-110M).","Exercised option to acquire Endospan; base price $175M, net ~$135M after offsetting loans; contingent consideration up to $200M; closing expected Q2 2026.","FDA approved NEXUS Aortic Arch System on April 2, 2026, triggering option exercise; commercial launch planned Jan 1, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":114504,"accession_number":"0001628280-26-007674","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q4 revenue $116M (+19%), GAAP net income $2.4M; full year $441M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP revenue Q4 $116.0M vs $97.3M, net income $2.4M ($0.05 diluted EPS) vs net loss $16.5M in Q4 2024.","Adjusted revenue (ex Italian reserve) $118.3M, up 18% constant currency; adjusted EBITDA $22.7M (+29%).","Full year 2025 GAAP revenue $441.3M vs $388.5M; GAAP net income $9.8M vs loss $13.4M.","Filed final PMA module for AMDS Hybrid Prosthesis with FDA; positive NEXUS TRIOMPHE clinical data at STS meeting.","Non-GAAP net income Q4 $8.6M ($0.17 per share); full year $29.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":441330000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":130879,"accession_number":"0001628280-25-050164","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q3 rev $113.4M (+18% YoY), net income $6.5M; raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $113.4M, up 18% GAAP/16% constant currency YoY; net income $6.5M ($0.13 EPS) vs loss of $2.3M.","Adjusted EBITDA $24.6M, up 39% from $17.7M; non-GAAP EPS $0.16 vs $0.12.","Stent grafts +38%, On-X +25%, preservation +5%, BioGlue +2% YoY.","Enrolled first patient in ARTIZEN IDE trial for Arcevo; refinanced credit to 2031 with $150M delayed draw.","Raises FY 2025 revenue guidance to $439-$445M (prev $435-$443M) and EBITDA to $88-$91M (prev $86-$91M)."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":325338000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147449,"accession_number":"0001628280-25-043099","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Artivion (AORT) to acquire two Austin office/manufacturing buildings for $20.5M cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Purchase price $12.05M for existing On-X manufacturing buildings (75k sq ft) and $8.45M for adjacent 87k sq ft expansion.","Both properties in Austin, TX are currently leased and occupied by Artivion; 1300 Property lease to terminate at closing unless assigned.","Company has sole discretion to cancel: 45-day feasibility period for 1300 Property, 100-day for 1200 Property.","Closings expected within 30 days after each feasibility period; escrow deposit of $126K for 1300 Property.","Cash consideration; agreements contain customary representations, warranties, and conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147448,"accession_number":"0000784199-25-000145","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-09-15T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Artivion extends credit facility maturities to 2031, adds $150M delayed draw term loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Maturity of existing term loans and revolving credit facility extended to January 18, 2031.","New $150.0 million secured delayed draw term loan facility added, available until Sept 12, 2027.","Interest rate margins reduced: Term loans at SOFR+4.75% (or base+3.75%); revolver at SOFR+3.50% (or base+2.50%).","Proceeds usable for permitted acquisitions, investments, and capex; no scheduled principal payments before final maturity.","Prepayment premium of 1.00% applies if prepayment of term loans occurs before July 18, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147447,"accession_number":"0000784199-25-000136","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Artivion appoints Lance Berry as COO, retains CFO role; CMO Stanton to retire March 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Lance Berry appointed COO effective Aug 11, 2025, while continuing as CFO and Treasurer.","Berry receives $540k salary, 70% bonus target, $2.25M equity grant target for 2026.","Marshall Stanton, SVP Clinical Research and CMO, to retire effective March 31, 2026.","Stanton will provide transition services for up to one year post-retirement; no disagreement involved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":147446,"accession_number":"0001628280-25-038873","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q2 revenue $113.0M (+15% YoY), net income $1.3M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $113.0M vs $98.0M YoY; GAAP net income $1.3M ($0.03 EPS) vs net loss $(2.1M) prior year.","Non-GAAP net income $10.7M ($0.24 EPS) vs $2.9M ($0.07) YoY; adjusted EBITDA $24.8M (+33%).","On-X +24%, stent grafts +24%, BioGlue +4%, Preservation +3% constant currency growth.","FY 2025 guidance raised: constant currency growth now 12-14%; reported revenue $435-443M.","Retired $99.5M of convertible notes; FDA IDE approved for Arcevo LSA pivotal trial."],"consensus_eps_estimate":null,"consensus_eps_actual":0.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":211950000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166085,"accession_number":"0000784199-25-000129","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Artivion exchanges $99.5M of convertible notes for 4.3M shares; nearly eliminates 2025 debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Exchanged $99.54M principal of 4.250% convertibles due 2025 for 4,334,347 shares of common stock.","Cash payment of $1.7M made for accrued interest on the exchanged Notes.","Only $0.46M in aggregate principal of the Notes remains outstanding after closing.","CEO states transaction significantly reduces leverage ratios and enhances balance sheet flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166084,"accession_number":"0000784199-25-000083","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-05-16T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Artivion shareholders approve 3.57M share increase for equity incentive plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; say-on-pay and auditor ratification approved.","Additional 3,570,000 shares approved for Amended and Restated 2020 Equity and Cash Incentive Plan.","Total shares available under the plan now 9,285,000 shares.","The amended plan includes updated provisions for Options, SARs, Other Stock Awards, and Cash-Based Awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166083,"accession_number":"0000784199-25-000080","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["3.02","8.01","9.01"],"status":"ready","headline":"Artivion agrees to exchange ~$95M of 2025 convertible notes for common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Enters private exchange agreements with holders of 4.250% convertible notes due July 2025; ~$94.54M principal to be exchanged for shares.","Number of shares to be determined by 4-day VWAP beginning May 15; illustratively ~4.1M shares at $28.91 closing price.","Cash payment for accrued interest; transaction expected to close May 28, 2025.","After exchange, only $5.46M of notes remain outstanding, reducing near-term debt maturity risk.","Shares issued in private placement under Section 4(a)(2); J. Wood Capital Advisors acted as financial advisor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":166082,"accession_number":"0000784199-25-000069","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q1 revenue $99M (+2% GAAP), net loss $0.5M; raises FY 2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $99.0M, up 2% GAAP (4% constant currency); net loss $(0.5)M vs net income $7.5M in Q1 2024.","Non-GAAP net income $2.5M ($0.06 diluted); adjusted EBITDA $17.5M (+1% YoY).","Product growth: stent grafts +14%, On-X +10%, BioGlue +7%; preservation services -23% from cyber backlog.","FY 2025 guidance raised: revenue $423-435M (11-14% constant currency growth); adj. EBITDA $84-91M.","Positive 30-day NEXUS data (63% MAE reduction); PMA submitted for AMDS Hybrid Prosthesis to FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":98978000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":183598,"accession_number":"0000784199-25-000012","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2025-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q4 revenue $97.3M (+4% YoY); FY2025 revenue guidance $420-435M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $97.3M (+4% GAAP, +3% constant currency); On-X, stent grafts, BioGlue each grew 8-10%.","Q4 net loss $(16.5)M ($0.39/share) vs loss $(4.0)M prior year; Adjusted EBITDA $17.6M (+15%).","FY2024 revenue $388.5M (+10% GAAP), net loss $(13.4)M vs $(30.7)M in 2023; Adjusted EBITDA $71.3M (+32%).","FDA granted Humanitarian Device Exemption for AMDS; second PMA module submitted; clinical data showed 50% mortality reduction.","FY2025 revenue guidance $420-435M (10-14% constant currency growth); adjusted EBITDA $84-91M (18-28% growth)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":388537000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200185,"accession_number":"0000784199-24-000265","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Artivion changes conversion settlement method on its 4.25% Convertible Notes due 2025 to Physical Settlement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On Dec 23, 2024, Artivion notified holders it is changing the default settlement method for its convertible notes to Physical Settlement.","All conversions after the notice date will be settled by delivering shares of common stock instead of cash or a combination.","The notes are the 4.250% Convertible Senior Notes due 2025 governed by the Indenture dated June 23, 2020.","The change affects dilution: conversions will now increase outstanding share count rather than reduce cash."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200184,"accession_number":"0000784199-24-000254","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA grants Artivion HDE for AMDS Hybrid Prosthesis in acute DeBakey Type I dissections with malperfusion","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["HDE covers ~40% of US acute DeBakey Type I dissections; PMA expected late 2025 for full $150M annual market.","PERSEVERE trial: 72% reduction in all-cause mortality, 54% reduction in major adverse events vs. standard hemiarch at 30 days.","AMDS is world's first aortic arch remodeling device; previously granted Breakthrough and HUD designations.","Company to begin IRB approvals, VAC submissions, and surgeon training to prepare for commercial launch.","Enterprise shareholders to receive 0.60 Independent shares + $2.00 cash per share; total consideration ~$562M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200183,"accession_number":"0000784199-24-000253","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-12-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Artivion reports cybersecurity incident discovered Nov 21; systems taken offline","summary_kind":"llm","event_type":"cyber","confidence":"medium","bullets":["Incident involved acquisition and encryption of files; external advisors engaged.","Systems taken offline; restoration underway; order/shipping disruptions largely mitigated.","Company believes incident not material to financial condition or operations currently.","Expects additional uninsured costs; cannot rule out future material impact.","No determination on notification obligations yet; insurance coverage exists."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":200182,"accession_number":"0000784199-24-000234","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q3 revenue $95.8M (+9% YoY); EBITDA $17.7M (+28%); guides FY $389-396M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $95.8M (+9% GAAP, +10% constant currency); net loss ($2.3M) ($0.05 EPS) vs ($9.8M) ($0.24) prior year.","Non-GAAP net income $5.0M ($0.12 EPS) vs $0.7M ($0.02); includes $2.4M foreign currency gains.","Adjusted EBITDA $17.7M (+28%); FY guidance narrowed to $389-396M revenue and $69-72M EBITDA.","On-X +15%, BioGlue +14%, stent grafts +12%; APAC +23% and LatAm +21% (constant currency +32%).","Regulatory milestones: AMDS PMA module submitted, BioGlue approved in China, NEXUS TRIOMPHE enrollment complete."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":291229000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216207,"accession_number":"0000784199-24-000211","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q2 revenue $98M (+10% YoY), narrows net loss, raises FY24 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $98.0M (+10% GAAP and constant currency); net loss ($2.1M) vs ($3.4M) YoY.","Non-GAAP net income $2.9M ($0.07 EPS) vs $2.3M ($0.06 EPS) YoY.","Adjusted EBITDA $18.6M, up 35% from $13.8M in Q2 2023.","Raised FY24 constant currency revenue growth to 10-12% (prev 9-12%), implied revenue $388-396M.","Raised FY24 adjusted EBITDA growth to 28-34% (prev 26-34%), implied EBITDA $69-72M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":195450000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":216206,"accession_number":"0000784199-24-000207","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-07-01T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Artivion provides $25M additional loans to Endospan, reduces purchase option to $135M net","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Up to $25M in three tranches ($7M upfront) to fund NEXUS FDA approval; loan secured by first-priority lien.","Purchase option upfront payment reduced from $250M to $175M; net to $135M after loan offset.","$100M minimum earnout eliminated; earnout now 2.5x incremental year-2 revenue (max $200M).","Company does not expect material impact on FY2024 guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235749,"accession_number":"0000784199-24-000184","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-05-17T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Artivion amends bylaws, narrows stockholder advance notice requirements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended bylaws effective May 15, 2024; updates advance notice rules for stockholder nominations and proposals.","Removed requirements to disclose performance fees, interests in contracts with affiliates/competitors, and info on 'others acting in concert'.","Narrowed 'Stockholder Associated Person' definition to beneficial owner only; removed requirement for nominee interviews.","Updated provisions for committee appointments and board consent effectiveness under DGCL Sections 141(c) and 141(f).","Clarified indemnification expenses exclude settlement payments for actions by/right of corporation per DGCL Section 145(b)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235748,"accession_number":"0000784199-24-000181","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Artivion stockholders approve officer exculpation charter amendment at 2024 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved amendment to certificate of incorporation allowing officer exculpation under Delaware law; effective May 15, 2024.","All nine director nominees elected; non-binding say-on-pay and auditor ratification also approved.","Officer exculpation vote: 30,848,088 For, 1,866,048 Against, 4,121,060 broker non-votes.","Ernst & Young LLP ratified as independent auditor for fiscal year ending December 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":235747,"accession_number":"0000784199-24-000169","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q1 revenue $97.4M (+17% YoY); nets $7.5M income vs loss; raises FY24 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $97.4M, up 17% GAAP (16% constant currency) vs $83.2M in Q1 2023.","Net income $7.5M ($0.18 diluted EPS) vs net loss ($13.5M) in Q1 2023; non-GAAP net income $2.6M ($0.06 EPS).","Non-GAAP adjusted EBITDA rose 60% to $17.3M from $10.8M in Q1 2023.","Revised FY24 constant-currency revenue growth guidance to 9%-12% (prev 8%-12%); revenue range $386M-$396M.","Tissue processing +26% constant currency YoY; stent grafts +19%; Latin America +22% constant currency."],"consensus_eps_estimate":null,"consensus_eps_actual":0.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":97431000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253502,"accession_number":"0000784199-24-000013","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-02-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q4 revenue $93.7M (+18% YoY); guides 2024 rev $382-396M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $93.7M (+18% GAAP, +15% constant currency); full year $354.0M (+13%).","Q4 non-GAAP net income $4.6M ($0.11 EPS); adjusted EBITDA $15.3M (+40% YoY).","Full year net loss ($30.7M); non-GAAP net income $8.4M ($0.20 EPS); free cash flow $11.4M.","2024 guidance: revenue $382-396M (+8-12%), adjusted EBITDA $68-72M (+26-34%).","AMDS PERSEVERE trial met endpoints: 72% mortality reduction, 52% fewer MAEs; FDA PMA expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":354004000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":253501,"accession_number":"0000950157-24-000061","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Artivion enters $350M credit facility with Ares Capital, refinances existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Entered $350M credit facility: $190M initial term loan, $100M delayed draw term loan, $60M revolving credit facility.","Borrowed $190M + $30M revolver on Jan 18, 2024; proceeds used to refinance existing credit facilities and pay fees.","Term loans: SOFR+6.50% (or Base+5.50%); revolver: SOFR+4.00% (or Base+3.00%); maturity Jan 18, 2030.","Delayed draw term loan may be used solely to repurchase/repay 4.250% convertible senior notes due July 2025.","Facilities secured by substantially all assets; includes covenants including maximum total net leverage ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270968,"accession_number":"0000784199-23-000155","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2023-12-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Artivion appoints Lance A. Berry as CFO; Ashley Lee to retire after nearly 30 years","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["D. Ashley Lee, EVP & CFO, retires effective Dec 31, 2023; will serve as consultant for 1 year.","Lance A. Berry, former CFO of Wright Medical, appointed CFO and Treasurer effective Dec 4, 2023.","Berry's compensation: $500K base, sign-on equity of $1.5M (options/RSUs), 60% bonus target.","Artivion reaffirms full-year 2023 financial guidance provided on Nov 2, 2023.","Berry also serves on boards of Treace Medical Concepts and Vapotherm."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":270967,"accession_number":"0000784199-23-000146","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2023-11-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q3 revenue $87.9M (+14% YoY); raises FY2023 revenue and EBITDA guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $87.9M, up 14% GAAP and 12% constant currency vs Q3 2022; net loss ($9.8M) or ($0.24)/share.","Non-GAAP net income $749k ($0.02/share) vs ($1.9M) loss a year ago; adjusted EBITDA up 34% to $13.9M.","Aortic stent graft revenue surged 30% GAAP (22% constant currency); On-X revenue up 14% (13% cc).","FY2023 revenue guidance raised to $349-351M (prior $342-350M); constant currency growth now 11-12%.","Expects 2023 adjusted EBITDA >$52M (+25% YoY); PERSEVERE trial enrollment nearing completion (90 of 93)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":260334000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287861,"accession_number":"0000784199-23-000139","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Artivion amends Bylaws to adopt universal proxy card rules and update governance provisions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extends stockholder notice period for director nominations and business proposals.","Requires nominating stockholders to use non-white proxy cards and comply with SEC Rule 14a-19.","Nominating stockholders must solicit minimum share percentages specified under universal proxy rules.","Updates regulations on cell phones, recording devices at meetings; conforms to DGCL Sections 116, 216, 219, 222.","Amendments effective September 1, 2023; other ministerial and clarifying changes included."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":287860,"accession_number":"0000784199-23-000130","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q2 revenue $89.3M (+11% YoY); raises FY revenue guidance to $342-350M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss ($3.4M) or ($0.08)/share; non-GAAP net income $2.3M ($0.06)/share.","Non-GAAP adjusted EBITDA $13.8M, up 35% YoY.","Aortic stent graft revenue +19% YoY; On-X +11% constant currency.","Received $14.3M PerClot PMA approval milestone payment from Baxter.","FY 2023 constant currency revenue growth guidance raised to 10%-12%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":172480000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308195,"accession_number":"0000784199-23-000092","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2023-05-19T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Artivion shareholders approve additional 3.04M shares for equity plan, re-elect directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved 3,040,000 additional shares for the 2020 Equity and Cash Incentive Plan (30,752,663 for, 886,740 against).","All 9 director nominees elected; each received >26M votes for (broker non-votes 3,436,309).","Say-on-pay approved with 27,174,737 votes for, 4,460,348 against; one-year frequency for future votes approved.","Ernst & Young LLP ratified as independent auditor for FY 2023 (35,117,916 for, 104,825 against).","Plan details filed as Exhibit 10.1; maximum shares available adjusted to 5,715,000 plus remainder from previous plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":308194,"accession_number":"0000784199-23-000084","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q1 revenue $83.2M (+8% GAAP, +10% constant currency); raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss ($13.5M) or ($0.33)/share; non-GAAP net income $769k ($0.02)/share.","On-X revenue up 24% constant currency; aortic stent grafts up 8% constant currency.","FY 2023 revenue guidance raised to $337-348M (prev. $331-343M); constant currency growth now 9-12%.","Adjusted EBITDA guidance increased to >$52M (prev. >$50M); EBITDA growth >25% YoY expected.","FDA issued Approvable Letter for PerClot PMA; $14.3M milestone payment expected after final approval."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":83229000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":327061,"accession_number":"0000784199-23-000014","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2023-02-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q4 GAAP EPS $0.05 vs ($0.51) loss; 2023 revenue outlook $331M-$343M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $79.4M, flat GAAP, +5% constant currency; On-X +11% CC, aortic stent grafts +16% CC.","GAAP net income $2.2M ($0.05 EPS) vs net loss $20.1M ($0.51); non-GAAP $4.2M ($0.10).","FY2022 revenue $313.8M (+5% GAAP, +9% CC); net loss $19.2M ($0.48) vs $14.8M ($0.38) in 2021.","Received CE mark for BioGlue under EU MDR in Q4 2022.","2023 guidance: CC revenue growth 8-12%, revenue $331M-$343M, adjusted EBITDA >$50M (+20%)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":313789000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344794,"accession_number":"0000784199-22-000193","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Artivion grants $6.6M in RSUs and options to executives; accelerates 2023 equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total grant date fair value of $6.6M under 2020 Equity and Cash Incentive Plan on Nov 8, 2022.","CEO J. Patrick Mackin receives 116,954 RSUs and 280,435 options at $11.03 strike; other NEOs get smaller grants.","Compensation Committee accelerated part of the 2023 annual equity award to retain executives amid weak prior grants.","Remaining 2023 annual grant expected in Q1 2023, likely including performance-contingent share units."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":344793,"accession_number":"0000784199-22-000184","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q3 revenue $76.8M (+6% GAAP, +11% constant currency); net loss $0.34/share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $76.8M, up 6% GAAP and 11% constant currency vs Q3 2021.","On-X revenues up 17% GAAP and 19% constant currency; tissue processing up 13% constant currency.","Net loss ($13.7M) or ($0.34)/share vs net income $10.6M ($0.26) in Q3 2021. Includes $4.7M PROACT Xa termination charge and $3.7M FX loss.","Non-GAAP net loss ($1.9M) or ($0.05)/share vs ($1.2M) ($0.03) prior year.","2022 outlook: narrowing constant currency revenue growth to 9-10%; full-year revenue expected $313M-$316M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":234391000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361272,"accession_number":"0000784199-22-000174","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-09-29T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Artivion appoints Elizabeth Hoff to Board of Directors effective Oct 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded to nine directors; Hoff appointed to Compliance Committee.","Hoff brings 30+ years medical device experience including aortic space at Guidant, W.L. Gore, Medtronic.","Board determined Hoff qualifies as independent under NYSE standards.","Hoff will receive same equity and cash compensation as other non-employee directors per April 2022 proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361271,"accession_number":"0000784199-22-000171","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-09-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Artivion stops PROACT Xa trial; apixaban fails non-inferiority vs warfarin for On-X aortic valves","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommended stopping PROACT Xa due to lack of evidence supporting non-inferiority of apixaban to warfarin.","Blood clots causing stroke occurred more frequently in patients receiving apixaban; trial continuation unlikely to achieve primary endpoint.","Physicians notified to switch apixaban-arm patients back to warfarin.","Successful trial would have significantly increased addressable market beginning in 2025; that opportunity is now lost.","Company reaffirms 2022 double-digit top-line growth and redirects ~$10M annual trial funding to other development and EBITDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361270,"accession_number":"0000784199-22-000163","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["5.05","9.01"],"status":"ready","headline":"Artivion board approves amended Code of Conduct in routine governance review","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amended and restated Code of Conduct on August 2, 2022, effective immediately.","Amendments streamline and improve readability; no waivers were granted or implied.","Code applies to all officers, employees, and directors; available on company website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":361269,"accession_number":"0000784199-22-000157","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-08-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q2 revenue $80.3M (+6% GAAP, +9% CC); net loss widens to $4.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $80.3M vs $76.1M YoY; constant currency growth of 9%.","GAAP net loss $4.3M ($0.11/sh) vs $2.2M ($0.06) YoY; non-GAAP net loss $1.3M ($0.03).","Aortic stent graft revenue up 23% CC; On-X revenue up 12% CC; Asia Pacific +38% CC.","Full-year 2022 constant currency revenue growth guidance reaffirmed at 9%-11%.","Enrolled first patients in US AMDS clinical trial (PERSEVERE); expects FDA PMA approvals for PROACT Mitral and PerClot this year."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":157553000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380530,"accession_number":"0000784199-22-000127","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-05-20T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Artivion shareholders elect directors, approve compensation and ESPP amendment at 2022 Annual Meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All eight director nominees elected; votes for ranged from 26.6M (Burbank) to 29.3M (Borgstrom, Semedo).","Say-on-pay approved with 28.1M for, 1.1M against, 158K abstain, and 4.5M broker non-votes.","Ratification of Ernst & Young as auditor for FY2022 passed with 33.5M for, 333K against.","Approval of Amended and Restated Employee Stock Purchase Plan (2.9M shares authorized) with 29.3M for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":380529,"accession_number":"0000784199-22-000122","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q1 revenue up 8.6% to $77.2M; net loss of $0.08 per share","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $77.2M, +8.6% GAAP YoY; constant currency growth 11.2% driven by aortic stent grafts (+34%) and On-X (+11%).","Net loss $3.4M ($0.08/share) vs $3.1M loss in Q1 2021; non-GAAP net income $1.1M ($0.03/share) vs $1.4M.","Asia Pacific constant currency revenue +39%; Latin America +93%. Pipeline progress: PROACT Mitral and PerClot FDA PMA expected in 2022.","FY 2022 constant currency revenue growth guidance reaffirmed at 9.0%-11.0%."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":77213000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398610,"accession_number":"0000784199-22-000034","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-02-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Artivion Q4 revenue record $79.4M (+16.9%), net loss widens to $20.1M; guides 2022 rev $319-325M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $79.4M, up 16.9% GAAP; net loss ($20.1M) vs ($3.5M) in prior year.","Non-GAAP Q4 net loss ($141K) vs income $7.9M; full year non-GAAP net income $4.9M.","Full year revenue $298.8M (+18%); net loss ($14.8M) narrowed from ($16.7M) in 2020.","2022 outlook: constant currency revenue growth 9-11%; GAAP revenue $319-325M with $6M FX headwind.","FDA approved AMDS trial start; PMA filed for PerClot US approval; PROACT trials progressing."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":298836000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398609,"accession_number":"0000784199-22-000014","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-01-20T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"CryoLife rebrands as Artivion; ticker changes to AORT from CRY effective Jan 24","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company renamed from CryoLife, Inc. to Artivion, Inc., effective January 18, 2022.","NYSE ticker changes from CRY to AORT, effective January 24, 2022.","Name reflects strategic focus on aortic disease; press release issued January 18, 2022.","Investor & Analyst Day scheduled for March 23, 2022 in New York City.","No changes to stockholder rights or other charter provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":398611,"accession_number":"0000784199-22-000006","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2022-01-04T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"CryoLife reincorporates from Florida to Delaware effective Jan 1, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reincorporation from Florida to Delaware effective Jan 1, 2022; approved by stockholders on Nov 16, 2021.","Each outstanding share of Florida common stock converted 1:1 to Delaware common stock with $0.01 par value.","All officers and directors continue in their roles with the Delaware corporation.","Certain stockholder rights changed, including adoption of exclusive forum provision (see proxy statement).","Fiscal year unchanged; reincorporation intended to be tax-free reorganization under Section 368(a)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417616,"accession_number":"0000784199-21-000211","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2021-11-18T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"CryoLife shareholders approve reincorporation from Florida to Delaware at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["78% of outstanding shares represented; all three proposals passed with large majorities.","Reincorporation approved: 30,214,640 for, 358,217 against, 125,013 abstain.","Exclusive forum provision approved: 27,052,290 for, 3,541,055 against, 131,524 abstain.","Adjournment proposal approved: 24,968,570 for, 5,550,631 against, 178,668 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":417615,"accession_number":"0000784199-21-000203","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2021-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"CryoLife Q3 revenue $72.2M (+11% YoY); net income $10.6M; non-GAAP EPS ($0.03)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $72.2M, up 11% GAAP and 9% constant currency vs Q3 2020.","GAAP net income $10.6M ($0.26 EPS) vs net loss ($2.9M) year ago.","Non-GAAP net loss ($1.2M) ($0.03 EPS) vs prior non-GAAP net income $4.9M ($0.13).","2021 outlook: full-year revenue $296-299M; Q4 $76.5-79.5M, pro forma constant currency growth 9.5-13.7% vs Q4 2019.","Submitted PMAs to FDA for PerClot and PROACT Mitral; approvals expected in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":219442000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435181,"accession_number":"0000784199-21-000198","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2021-09-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CryoLife appoints Anthony Semedo to board; director Ronald McCall passes away","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anthony Semedo appointed as director effective Oct 1, 2021; has 40+ years in med device, most recently at Medtronic.","Semedo will serve on Compliance Committee; qualifies as independent under NYSE standards.","Ronald McCall, director since 1984 and Presiding Director until March 2021, unexpectedly died on Sept 20, 2021.","Semedo receives same equity/cash compensation as other non-employee directors, per 2021 proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":435180,"accession_number":"0000784199-21-000183","cik":784199,"company_name":"ARTIVION, INC.","ticker":"AORT","form_type":"8-K","filed_at":"2021-07-29T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"CryoLife sells PerClot to Baxter for up to $60.8M; Q2 revenue up 42% to $76.1M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total consideration up to $60.8M: $25M at closing ($19M to CryoLife), $25M upon FDA PMA approval, $10M sales milestones.","CryoLife retains FDA costs through Dec 31, 2022; Baxter may assume after Jan 1, 2023.","Q2 2021 revenue $76.1M, up 42% GAAP vs Q2 2020 $53.8M; net loss ($2.2M) ($0.06/shr); non-GAAP net income $4.8M ($0.12/shr).","FY2021 revenue guidance $296-300M; Q3 2021 expected $71-73M, with PerClot minimal in H2 due to sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1101934060.9578204,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}